Introduction: Gastric carcinoma is a leading cause of cancer-related mortality worldwide, particularly prevalent in Eastern Asia. Beta-catenin, a key protein involved in cell adhesion, differentiation, and proliferation, has been implicated in the progression of various cancers, including gastric carcinoma. Dysregulation of beta-catenin is associated with poor prognosis, but its correlation with specific clinicopathological features in gastric carcinoma remains unclear. This study aims to investigate beta-catenin expression in gastric carcinoma tissues and its association with clinicopathological features. Methods: An observational study was conducted involving 50 patients diagnosed with gastric carcinoma. Immunohistochemistry was used to evaluate beta-catenin expression in resected tumor tissues. The staining intensity and percentage of positively stained cells were assessed by two independent pathologists. Clinicopathological data, including age, gender, tumor size, depth of invasion, lymph node metastasis, and TNM stage, were collected and analyzed using chi-squared or Fisher's exact test. Results: Beta-catenin expression was high in 36% (18/50) of the patients and low in 64% (32/50). High beta-catenin expression significantly correlated with advanced TNM stage (P=0.03) and deeper tumor invasion (P=0.02). However, no significant correlation was found between beta-catenin expression and age, gender, tumor size, or lymph node metastasis. Discussion: The findings indicate that beta-catenin may play a significant role in gastric carcinoma progression, particularly in tumor invasion and staging. These results align with previous studies that suggest beta-catenin as a potential therapeutic target in gastric carcinoma. The study's limitations, including its small sample size, highlight the need for further research to confirm these associations and explore the therapeutic potential of beta-catenin inhibition. Conclusion: This study provides evidence of the association between beta-catenin expression and advanced gastric carcinoma features, suggesting that beta-catenin could be a valuable target for therapeutic strategies. Further research is necessary to elucidate the underlying mechanisms and validate beta-catenin as a therapeutic target in gastric carcinoma.

Gastric carcinoma is a leading cause of cancer-related mortality worldwide, particularly prevalent in Eastern Asia.